TTY Biopharm Co (ROCO:4105) EV-to-EBIT : 12.47 (As of Apr. 27, 2024)

View and export this data going back to 2001. Start your Free Trial

What is TTY Biopharm Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TTY Biopharm Co's Enterprise Value is NT$18,145 Mil. TTY Biopharm Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$1,455 Mil. Therefore, TTY Biopharm Co's EV-to-EBIT for today is 12.47.

The historical rank and industry rank for TTY Biopharm Co's EV-to-EBIT or its related term are showing as below:

ROCO:4105' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.33 Med: 15.5 Max: 111.37
Current: 12.47

During the past 13 years, the highest EV-to-EBIT of TTY Biopharm Co was 111.37. The lowest was 9.33. And the median was 15.50.

ROCO:4105's EV-to-EBIT is ranked better than
65.42% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs ROCO:4105: 12.47

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. TTY Biopharm Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$19,655 Mil. TTY Biopharm Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$1,455 Mil. TTY Biopharm Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 7.40%.

TTY Biopharm Co EV-to-EBIT Historical Data

The historical data trend for TTY Biopharm Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TTY Biopharm Co EV-to-EBIT Chart

TTY Biopharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

16.23

14.14

15.65

14.32

13.51

TTY Biopharm Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															14.32	12.84	13.23	12.39	13.51

Competitive Comparison of TTY Biopharm Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TTY Biopharm Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TTY Biopharm Co's EV-to-EBIT falls into.

TTY Biopharm Co EV-to-EBIT Calculation

TTY Biopharm Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	18145.077	/	1454.825
	=	12.47

TTY Biopharm Co's current Enterprise Value is NT$18,145 Mil.
TTY Biopharm Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,455 Mil.

TTY Biopharm Co (ROCO:4105) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

TTY Biopharm Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	1454.825	/	19654.749
	=	7.40 %

TTY Biopharm Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$19,655 Mil.
TTY Biopharm Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,455 Mil.

TTY Biopharm Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of TTY Biopharm Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

TTY Biopharm Co (ROCO:4105) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TTY Biopharm Co Ltd (ROCO:4105) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503

Website

https://www.tty.com.tw

TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segment includes Oncology, Health Care, Anti-Infection, Domestic Cardiovascular and Gastrointestinal Drugs, and other segments. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

TTY Biopharm Co (ROCO:4105) Headlines

No Headlines